PPGN.SW
PolyPeptide Group AG
Price:  
40.05 
CHF
Volume:  
21,455.00
Switzerland | Life Sciences Tools & Services
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

PPGN.SW WACC - Weighted Average Cost of Capital

The WACC of PolyPeptide Group AG (PPGN.SW) is 6.7%.

The Cost of Equity of PolyPeptide Group AG (PPGN.SW) is 6.75%.
The Cost of Debt of PolyPeptide Group AG (PPGN.SW) is 6.85%.

Range Selected
Cost of equity 5.50% - 8.00% 6.75%
Tax rate 6.90% - 9.40% 8.15%
Cost of debt 4.00% - 9.70% 6.85%
WACC 5.3% - 8.1% 6.7%
WACC

PPGN.SW WACC calculation

Category Low High
Long-term bond rate 1.0% 1.5%
Equity market risk premium 5.1% 6.1%
Adjusted beta 0.89 0.99
Additional risk adjustments 0.0% 0.5%
Cost of equity 5.50% 8.00%
Tax rate 6.90% 9.40%
Debt/Equity ratio 0.1 0.1
Cost of debt 4.00% 9.70%
After-tax WACC 5.3% 8.1%
Selected WACC 6.7%

PPGN.SW's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for PPGN.SW:

cost_of_equity (6.75%) = risk_free_rate (1.25%) + equity_risk_premium (5.60%) * adjusted_beta (0.89) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.